Opinion|Videos|September 3, 2025
Highlighting Deuruxolitinib for Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Mostaghimi: Deuruxolitinib has been evaluated in the
THRIVE-AA1 andTHRIVE-AA2 multinational phase 3 clinical trials gaining FDA approval in 2024. How did this JAK inhibitor differ from the last past two 2 JAK inhibitors approved in the previous 2 years?- Durability is often an issue seen in studies where patients don’t remain on therapies long-term. Why is it so important to see the majority of patients staying on deuruxolitinib through 24 weeks?
- How does the durability of the different JAK inhibitors compare?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Boston Panel Confronts Access and Coordination Gaps in Obesity Care
5